Contract manufacturers as a business (EMS, CMO, CRO)

“Väsentliga inverkningar, risker och möjligheter och deras förhållande till strategi och affärsmodell Råvaruutvinning och tillverkning av produkter som Alligo säljer sker genom komplexa leverantörskedjor, där leverantörerna främst finns i Norden, övriga Europa och Asien. Alligo har ingen egen tillverkning och saknar därmed direkt kontroll över produktionen.”

Annual report 2024A · The company itself

“In addition, some of these devices may be provided by single-source unaffiliated third-party companies. We are dependent on the sustained cooperation and effort of those third-party companies to supply and/or market the devices and, in some cases, to conduct the studies required for approval or clearance by the applicable regulatory agencies.”

Annual report 2025A · The company itself

“RISKS RELATED TO OPERATIONS We perform a substantial majority of our commercial manufacturing activities at our facility in the U.S. territory of Puerto Rico and a substantial majority of our clinical manufacturing activities at our facility in Thousand Oaks, California; significant disruptions or production failures at these facilities could significantly impair our ability to supply our products or continue our clinical trials. The global supply of our products and product candidates for commercial sales and for use in our clinical trials is significantly dependent on the uninterrupted and efficient operation of our manufacturing facilities, in particular those in the U.S. territory of Puerto Rico and Thousand Oaks, California.”

Annual report 2025A · The company itself

“We rely on unaffiliated third-party suppliers for certain raw materials, medical devices and components necessary for the manufacturing of our commercial and clinical products. Certain of those raw materials, medical devices and components are proprietary products of those unaffiliated third-party suppliers and are specifically cited in our drug applications with regulatory agencies so that they must be obtained from that specific sole source or sources and could not be obtained from another supplier unless and until the regulatory agency approved such supplier.”

Annual report 2025A · The company itself

“In addition, we use third-party contract manufacturers to produce, or assist in the production of, a number of our products, and we currently use contract manufacturers to produce, or assist in the production of, a number of our late-stage product candidates and drug delivery devices.”

Annual report 2025A · The company itself

“Our IC products are fabricated on proprietary processes at our internal production facilities in Wilmington, Massachusetts; Camas, Washington; Beaverton, Oregon; and Limerick, Ireland and also on a mix of proprietary and non-proprietary processes at third-party wafer fabricators. We currently source more than half of our wafer requirements annually from third-party wafer fabrication foundries, such as Taiwan Semiconductor Manufacturing Company (TSMC) and others, and the remainder is sourced internally.”

Annual report 2025A · The company itself

“If we are unable to manage our relationships with our third-party contract manufacturers effectively, or if these third-party manufacturers suffer delays or disruptions or quality control problems in their operations, experience increased manufacturing lead times, capacity constraints or fail to meet our future requirements for timely delivery, our ability to ship products to our customers would be severely impaired, and our business, financial condition, results of operations and prospects would be seriously harmed.”

Annual report 2025A · The company itself

“We may not be able to develop alternate or second contract manufacturers in a timely manner. If we add or change contract manufacturers or change any manufacturing plant locations within a contract manufacturer network, we would add additional complexity and risk to our supply chain management and may increase our working capital requirements. Ensuring a new contract manufacturer or new plant location is qualified and has sufficient manufacturing capacity to manufacture our products to our standards and industry requirements could take significant effort and be time consuming and expensive, and any delays or failures to adequately ramp production to meet our customer demand could negatively impact our business, financial condition, results of operations and prospects.”

Annual report 2025A · The company itself

“A new contract manufacturer or manufacturing location may not be able to scale its production of our products at the volumes or quality we require. This could also adversely affect our ability to meet our scheduled product deliveries to our customers, which could damage our customer relationships and cause the loss of sales to existing or potential customers, late delivery penalties, delayed revenue or an increase in our costs which could adversely affect our gross margins.”

Annual report 2025A · The company itself

“We depend on third-party contract manufacturers to manufacture our product lines. A significant portion of our cost of revenue consists of payments to these third-party contract manufacturers. Our reliance on these third-party contract manufacturers reduces our control over the manufacturing process, quality assurance, product costs and product supply and timing, which exposes us to operational risks including their ability to obtain sufficient components for our products in a timely manner and to ramp manufacturing sufficiently to meet our customer demand.”

Annual report 2025A · The company itself

“We do not have long-term contracts with our third-party manufacturers that guarantee capacity, the continuation of particular pricing terms or the extension of credit limits. Accordingly, they are not obligated to continue to fulfill our supply requirements, which could result in supply shortages, and the prices we are charged for manufacturing services could be increased on short notice.”

Annual report 2025A · The company itself

“The failure of any critical third party to satisfactorily meet its obligations, including for future royalty and milestone payments; to adequately deploy business continuity plans in the event of a crisis; and/or to satisfactorily resolve significant disagreements with us or address other factors, could have a material adverse impact on our business and results of operations.”

Annual report 2025A · The company itself

“We rely on suppliers, vendors, outsourcing partners, alliance partners and other third parties to research, develop, manufacture, commercialize, co-promote and sell our products, manage certain marketing, human resource, finance, IT, data and other business unit and functional services and meet their contractual, regulatory and other obligations.”

Annual report 2025A · The company itself

“Cavendish Hydrogen is also to a certain degree dependent on a limited number of third-party suppliers for key production components for its fueling station products.”

Annual report 2024A · The company itself

“Nevertheless, Cavendish does have a few single-source components and is at risk of temporary supply chain disruptions should one or more suppliers fail to deliver.”

Annual report 2024A · The company itself

“Another supply chain risk is whether suppliers can continue to operate under the uncertain market developments inherent in this industry.”

Annual report 2024A · The company itself

“Våra instrument tillverkas och monteras av en underleverantör vilket säkerställer möjlighet till en betydande skalbarhet. CellaVision ansvarar för produktdesign, instruktioner för montering och kvalitetskontroll samt inköp av strategiska komponenter. Underleverantören hanterar inköp av standardkomponenter, montering, kvalitetskontroll och utgående logistik.”

Annual report 2024A · The company itself

“Bolaget har samarbetat med en kontraktstillverkare sedan 2006 och har långvariga avtal med sina viktigaste underleverantörer. Detta till trots, kan avtal sägas upp.”

Annual report 2024A · The company itself

“The manufacturing of certain of our products is concentrated in one or more of our plants, contract manufacturers or other suppliers, with limited alternate qualified facilities available. Many of our manufacturing processes and those of our contract manufacturers and other suppliers are complex and present difficult technical challenges to obtain the manufacturing yields necessary to operate profitably and may require complex and specialized equipment which can be expensive to repair or replace with required lead times of up to a year. Any event that disrupts or otherwise negatively impacts manufacturing facilities, manufacturing systems or equipment, or contract manufacturers or other suppliers could result in the delivery of inferior products or affect our ability to meet customer requirements or service levels.”

Annual report 2025A · The company itself

“Ciena relies on a small number of contract manufacturers to perform the majority of the manufacturing for its products. If Ciena cannot effectively manage these manufacturers or forecast future demand, or if these manufacturers fail to deliver products or components on time, Ciena’s business and results of operations may suffer.”

Annual report 2025A · The company itself

“Table of Contents Manufacturing We rely on contract manufacturers for our manufacturing needs. We presently use a variety of independent third-party companies to provide services related to printed-circuit board assembly, in-circuit test, product repair, and product assembly.”

Annual report 2026A · The company itself

“Matterport relies on a limited number of suppliers to supply its hardware components for its cameras and other hardware products, including in some cases only a single supplier for some products and components. This reliance on a limited number of manufacturers increases its risks, since Matterport does not currently have proven reliable alternative or replacement manufacturers beyond these key parties.”

Annual report 2025A · The company itself

“We rely upon independent manufacturers for all of our production needs, and the failure of these manufacturers to manage these responsibilities would prevent us from filling customer orders, which would result in loss of sales and harm our relationships with customers. We rely upon independent manufacturers and their respective material suppliers for all of our production needs, the majority of which are located in Southeast Asia, predominantly in Vietnam and Indonesia, which exposes us to geographic concentration risk, including risks arising from regional economic, political, environmental, or operational conditions, and we do not have direct control over these manufacturers or their suppliers.”

Annual report 2026A · The company itself

“Our dependence on a limited number of key manufacturing partners may increase our exposure to disruptions, pricing changes, or capacity constraints. While we have long-standing relationships with most of these manufacturers, they could terminate our engagement, seek to increase their prices, or extract other concessions from us, and we may not be able to timely engage a suitable alternative.”

Annual report 2026A · The company itself

“Internationally, we distribute our products through warehouses and DCs managed by 3PLs in certain international locations. For example, we are currently transitioning certain international 3PL operations to a new partner.”

Annual report 2026A · The company itself

“In addition, significant portions of our products are assembled by contract manufacturers, primarily in locations in Asia.”

Annual report 2026A · The company itself

“Det finns en risk att de kontraktstillverkare som anlitats av Bolaget inte levererar i tid eller i enlighet med de kvalitetskrav som följer av parternas avtal eller tillämpliga lagar och regler, vilket kan innebära förseningar och/eller ökade kostnader för Bolagets kliniska studier.”

Annual report 2024A · The company itself

“Bolaget har ingen egen tillverkning, vilket medför att Bolaget är beroende av kontraktstillverkare och underleverantörer för tillverkning av den mängd prövningsläkemedel som behövs för genomförandet av kliniska prövningar.”

Annual report 2024A · The company itself

“För dessa produkter gäller stränga kvalitetskrav, såsom god tillverkningssed (GMP) och god distributionssed (GDP).”

Annual report 2024A · The company itself

“Manufacturing We outsource the manufacturing of our products to various manufacturing partners, including our primary third-party manufacturer service provider, Flex Ltd. ("Flex"), to manufacture our hardware systems according to our specifications.”

Annual report 2025A · The company itself

“We outsource the manufacturing of our security appliance products to contract manufacturing partners and original design manufacturing partners, including manufacturers with facilities located in Taiwan and other countries outside the United States such as Accton, IBASE, Micro-Star, Senao and Wistron.”

Annual report 2025A · The company itself

“Our proprietary ASIC, which are key to the performance of our appliances, are built by contract manufacturers including Renesas and Toshiba America. These contract manufacturers use foundries operated by TSMC or Renesas on a purchase-order basis, and these foundries do not guarantee their capacity and could delay orders or increase their pricing.”

Annual report 2025A · The company itself

“We depend on CMOs, CTLs and corporate partners to perform manufacturing and testing activities effectively and on a timely basis for the majority of our active pharmaceutical ingredients and drug products.”

Annual report 2025A · The company itself

“We, our CMOs, our CTLs and our corporate partners are subject to current Good Manufacturing Practices (“cGMP”), which are extensive regulations governing manufacturing processes, stability testing, record keeping and quality standards as defined by FDA and EMA.”

Annual report 2025A · The company itself

“Any adverse developments affecting or resulting from any single entity within our manufacturing operations or the operations of our CMOs, CTLs and corporate partners can result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the development and commercial supply of our products, which may result in us not being able to generate sufficient quantities of clinical or commercial product to meet market demand and may cause delays in our clinical trials and applications for regulatory approval.”

Annual report 2025A · The company itself

“We depend on relationships with third parties for sales and marketing performance, technology, development, logistics and commercialization of products. Failure to maintain these relationships, poor performance by these companies or disputes with these third parties could negatively impact our business.”

Annual report 2025A · The company itself

“Table of Content We depend on third-party suppliers, contract manufacturers (including original equipment and original design manufacturers), as well as single-source and limited source suppliers, and our financial results could suffer if we fail to manage these third party relationships effectively. Our operations depend on our ability to anticipate our needs for components, products, and services, as well as the ability of our manufacturers (including original equipment manufacturers, original and outsourced design manufacturers, and contract manufacturers), and suppliers to deliver sufficient quantities of quality components, products, and services at reasonable prices and in time for us to meet critical schedules for the delivery of our own products and services.”

Annual report 2025A · The company itself

“We may experience supply shortfalls or delays in shipping products to our customers if our manufacturers experience delays, disruptions, or quality control problems in their manufacturing operations, or if we have to change or add manufacturers or contract manufacturing locations.”

Annual report 2025A · The company itself

“We also rely upon the performance of the systems and processes of our contract manufacturers to build and ship our products. If those systems and processes experience interruption or delay, the manufacture and shipment of our products in a timely manner may be impaired.”

Annual report 2025A · The company itself

“We do not currently operate manufacturing facilities for most of our clinical or commercial products, including JAKAFI, PEMAZYRE, ICLUSIG, OPZELURA, ZYNYZ and NIKTIMVO, and our drug candidates. Our current manufacturing strategy for these products and drug candidates is to contract with third parties to manufacture the related raw materials, active pharmaceutical ingredient (“API”), and finished drug product.”

Annual report 2025A · The company itself

“We use the specific identification method to account for commercial product manufactured by third-party contractors, which is our predominant source of inventory.”

Annual report 2025A · The company itself

“We also produce our devices on manufacturing lines at a facility in China operated by a contract manufacturer.”

Annual report 2025A · The company itself

“While we manufacture our products in the United States and in Malaysia, a third-party contract manufacturer in China manufactures and supplies a significant portion of our inventory.”

Annual report 2025A · The company itself

“In addition, although we currently operate in-house manufacturing sites and source from hundreds of suppliers around the world, some of our products are currently manufactured at a single location or a limited number of locations. Despite our goal of having two or more active sources of supply for all critical materials or to build appropriate safety stock, we purchase certain key components and materials for our products, including APIs required to manufacture Tylenol®, from single-source suppliers or a limited number of suppliers.”

Annual report 2025A · The company itself

“Manufacturing Footprint Our in-house manufacturing footprint delivered approximately 60% of our sales volume during the fiscal year 2025, with the remaining sales volume being supplied by an extensive network of external manufacturing facilities operated by trusted third-party suppliers.”

Annual report 2025A · The company itself

“Risks Related to Our Operations We rely on third parties in many aspects of our business, including to manufacture certain of our products, which exposes us to additional risks that could adversely affect us. We rely on relationships with third parties, including manufacturers, suppliers, distributors, contractors, logistics providers, and other external business partners.”

Annual report 2025A · The company itself

“In particular, we partner with third parties to manufacture certain of our key products, such as Tylenol® and Zyrtec®.”

Annual report 2025A · The company itself

“We rely on the performance of a limited number of suppliers and manufacturers for our brewers, and a limited number of order fulfillment companies for our brewers, beverage concentrates, and syrups. A small number of companies, located primarily in Asia, co-manufacture the vast majority of our brewers.”

Annual report 2025A · The company itself

“Dependence on contract manufacturing and outsourcing other portions of our supply chain may adversely affect our ability to bring solutions to market and damage our reputation. Dependence on outsourced information technology and other administrative functions may impair our ability to operate effectively. As part of our efforts to streamline operations and to cut costs, we outsource aspects of our manufacturing processes and other functions and continue to evaluate additional outsourcing. If our contract manufacturers or other outsourcers fail to perform their obligations in a timely manner or at satisfactory quality levels, our ability to bring solutions to market and our reputation could suffer.”

Annual report 2025A · The company itself

“Commitments to contract manufacturers and suppliers. We purchase components from a variety of suppliers and use several contract manufacturers to provide manufacturing services for our products. See Note 14, “Commitments and Contingencies,” for additional information.”

Annual report 2025A · The company itself

“Sourcing and Manufacturing We obtain our fabrics and produce our products through a limited number of suppliers. We do not own or operate any manufacturing facilities.”

Annual report 2026A · The company itself

“We purchase raw materials, packages and components from a limited number of suppliers, who are often small and specialized. Additionally, some of our suppliers are our sole sources for certain materials, equipment and components.”

Annual report 2026A · The company itself

“We also rely on several independent contract manufacturers to supply us with certain products. For many products, a particular contract manufacturer may be the sole source of the finished good products.”

Annual report 2026A · The company itself

“As more companies focus on building leading edge products, our 17 Table of Contents manufacturing subcontractors are becoming capacity constrained in their ability to manufacture such products.”

Annual report 2026A · The company itself

“As a significant portion of our products are manufactured at foundries, foundry lead times may affect our ability to satisfy certain turns orders.”

Annual report 2026A · The company itself

“We are dependent on wafer foundries and other contractors, as are our SuperFlash and other licensees. We rely on outside wafer foundries for a significant portion of our wafer fabrication needs. Specifically, during fiscal 2026 and fiscal 2025, approximately 65% and 64%, respectively, of our net sales came from products that were produced at outside wafer foundries.”

Annual report 2026A · The company itself

“We also use several contractors for a portion of the assembly and testing of our products. Specifically, during fiscal 2026, approximately 33% of our assembly requirements and 31% of our test requirements were performed by third-party contractors compared to approximately 33% of our assembly requirements and 33% of our test requirements during fiscal 2025.”

Annual report 2026A · The company itself

“Additionally, if we have a need for greater manufacturing, assembly or test capacity in the future, or greater capacity for certain types of products, there can be no assurance that we will be able to secure the necessary allocation of capacity from our wafer foundries and other contractors with the process technologies that we need, or that such capacity will be available on acceptable terms. As our manufacturing subcontractors move to more advanced process technologies over time, we may find that they do not invest in some of the trailing edge process technologies on which a large portion of our products are manufactured.”

Annual report 2026A · The company itself

“We expect that our reliance on third party contractors may increase over time as our business grows, and any inability to secure necessary external capacity could adversely affect our operating results.”

Annual report 2026A · The company itself

“Transitioning production of products to new manufacturers may result in delayed product launches, reduced yields, or decreased product performance. If we encounter issues with product quality, insufficient capacity from a third-party manufacturer, or if we discontinue using a particular manufacturer or contractor, we may face challenges in securing an alternative supply for specific products in a timely manner. This could lead to significant delays in product shipments, potentially having an adverse impact on our results of operations.”

Annual report 2026A · The company itself

“In such event, we could experience an interruption in production, an increase in manufacturing costs or a decline in product reliability, and our business and operating results could be adversely affected.”

Annual report 2026A · The company itself

“Certain of our SuperFlash and other technology licensees rely on wafer foundries. If our licensees experienced disruption in supply at such foundries, this would reduce the revenue from our technology licensing business and would harm our operating results.”

Annual report 2026A · The company itself

“While we had approximately 101,000 customers, and our ten largest direct customers accounted for approximately 11% of our total revenue in fiscal 2026, and two of our top ten direct customers are contract manufacturers that perform manufacturing services for many customers, cancellation of customer contracts could have an adverse impact on our revenue and profits.”

Annual report 2026A · The company itself

“Produktion – Samarbete med kontraktstillverkare för att säker ställa effektiv och kvalitativ tillverkning av läkemedel.”

Annual report 2024A · The company itself

“Moberg Pharma använder kontraktstillverkare för produktionen, vilket gör att Bolaget är beroende av att externa leveranser uppfyller överenskomna krav vad gäller exempelvis mängd, kvalitet och leveranstid eller vad avser särskilt råmaterial. Det finns en risk att Moberg Pharma kan komma att drabbas av försenade eller uteblivna leveranser från dessa kontraktstillverkare, vilket kan komma att försena Bolagets försäljning av dess produktkandidater och påverka Bolagets likviditet negativt.”

Annual report 2024A · The company itself

“Bolaget har inte någon egen storskalig tillverkning, vilket medför att bolaget är beroende av en utomstående tillverkare för tillverkning av den mängd reningsmedia som behövs för att möta den efterfrågan som uppstår i relation till genomförandet av bolagets projekt och leveransavtal.”

Annual report 2024A · The company itself

“The Company is dependent on production and delivery of products from its third-party product suppliers. The Company has supply- and distribution agreements with suppliers in which the term of the agreement vary from one to eight years. The Company is dependent on renewing these agreements at fair prices and on market terms and conditions and is therefore in continuous dialogue with the key suppliers to ensure they are renewed at competitive terms.”

Annual report 2024A · The company itself

“Vi äger inga fabriker. Istället köper vi våra produkter från ett nätverk av tillverkare.”

Annual report 2024A · The company itself

“För närvarande samarbetar vi med 33 prioriterade fabriker. Vårt mål är att stå för 10-20 procent av varje tillverkares omsättning, alternativt att vara bland deras fem största kunder, för att med vår köpkraft säkerställa en nära relation och hög prioritering hos tillverkaren.”

Annual report 2024A · The company itself

“Manufacturing and Supply Chain We have outsourced manufacturing operations to third parties located in Fremont, California; San Jose, California; Laredo, Texas; Guadalajara, Mexico; Helmond, The Netherlands; Tiszaujvaros, Hungary; Taoyuan, Taiwan; and Singapore. These operations include materials procurement, commodity management, component engineering, test engineering, manufacturing engineering, product assembly, product assurance, quality control, final test, and global logistics.”

Annual report 2026A · The company itself

“NEXT has established outsourced production with strong partners in Asia with proven ability to produce large volumes of high quality and robust sensors for mass market deployment, which is highly recognized and appreciated by existing and potential new customers.”

Annual report 2024A · The company itself

“We rely on a concentrated base of contract manufacturers to supply a significant portion of our footwear products. We rely upon a concentrated amount of contract manufacturers, which we do not own or operate, to manufacture all of the footwear products we sell, see Item 1.”

Annual report 2026A · The company itself

“In addition, we cannot be certain that manufacturers that we do not contract and that we refer to as "unaffiliated manufacturers" will be able to fill our orders in a manner that is timely and compliant with applicable requirements.”

Annual report 2026A · The company itself

“Produktion samt avtal med underleverantörer och samarbetspartners Oncopeptides har ingen egen tillverkning varför bolaget är beroende av underleverantörer för läkemedelsproduktion. Substans och produkt ska produceras i tillräcklig kvantitet och av tillräcklig kvalitet.”

Annual report 2024A · The company itself

“Dessutom har bolaget outsourcat tillverkning, paketering, märkning och distribution samt utförandet av kliniska studier till underleverantörer. Bolaget är därför beroende av att upprätthålla dess underleverantörsavtal och skulle vidare påverkas om kostnaderna för sådana tjänster skulle öka väsentligt över tid.”

Annual report 2024A · The company itself

“RISKS RELATED TO OPERATIONS We depend on manufacturing partners and limited sources of supply for our hardware products, making us susceptible to manufacturing delays, supply shortages, pricing fluctuations, and international trade risks that could prevent timely shipment of customer orders and result in the loss of sales and end-customers.”

Annual report 2026A · The company itself

“We depend on manufacturing partners, primarily our EMS provider, Flex, to manufacture our hardware product lines.”

Annual report 2026A · The company itself

“We primarily utilize a fabless production model, which means that we do not own or operate foundries for the production of silicon wafers from which our integrated circuit products are made. Other than the facilities we own that manufacture certain of our RFFE modules and RF (radio frequency) filter products, we rely on third-party suppliers to perform the manufacturing and assembly, and most of the testing, of our integrated circuits.”

Annual report 2025A · The company itself

“Sourcing, Production and Quality We contract for the manufacture of our products with suppliers and do not own or operate any production facilities. Approximately 300 different suppliers worldwide produce our apparel, handbags, footwear & accessories, and home products, with no one supplier providing more than 5% of our total products (by dollar value) during Fiscal 2026.”

Annual report 2026A · The company itself

“Focus on supply chain excellence – More than a third of our revenue comes from manufacturing partners, highlighting a key strategic strength. These partners have a long-standing track record of providing a reliable outsourced manufacturing platform, enabling us to scale efficiently, enhance flexibility, and drive sustainable growth.”

Annual report 2025A · The company itself

“Risker relaterade till samarbeten med tredje parter Bolaget förlitar sig för närvarande, och kommer under överskådlig tid att fortsätta förlita sig, i stor utsträckning på vissa oberoende organisationers, rådgivares och konsulters tillhandahållande av vissa tjänster, inklusive i princip i allt som rör regulatoriska godkännanden, hanteringen av kliniska prövningar och tillverkning. Bolaget har exempelvis ingått avtal med tredje part avseende kemisk syntes, kliniska tester samt tillverkning av läkemedelssubstans för klinisk och kommersiell användning.”

Annual report 2024A · The company itself

“Även om Bolagets behov av läkemedelsutveckling till viss del täcks av intern expertis, är Bolaget också beroende av externa parter, såsom utredare och kliniska forskningsorganisationer. Därtill förlitar sig Bolaget på tredje parter för att tillverka sina produktkandidater och för preklinisk och klinisk leverans av sina produktkandidater.”

Annual report 2024A · The company itself

“Vår finansiella styrka kommer ytterligare gynnas av förvärvet av vår huvudleverantör Innovatif Cekal, som vi slutförde i slutet av november. När vi har sålt existerande lager förväntas denna affär förbättra vår marginal med 2 procentenheter, och därigenom ytterligare stärka vår långsiktiga lönsamhet.”

Annual report 2024A · The company itself

“I slutet av 2024 förvärvade Sedana Medical sin huvudleverantör i Malaysia vilket innebär att tillverkningen av Sedaconda ACD-produkterna numera sker i ett helägt dotterbolag.”

Annual report 2024A · The company itself

“Selvaag Bolig har ikke egen entreprenørvirksomhet, men inngår entrepriser på prosjektbasis. Dette gir selskapet mulighet til å kunne velge den beste og mest konkurransedyktige entreprenøren for hvert enkelt prosjekt.”

Annual report 2024A · The company itself

“In some instances, we depend on our relationships with our third-party foundries and packaging subcontractors to transition to smaller geometry processes successfully. Our manufacturing partners may not be able to effectively manage the transition, or we may not be able to maintain our relationships with certain manufacturing partners. If our manufacturing partners or we experience significant delays in this transition or fail to efficiently implement this transition, our business, results of operations, and financial condition could be materially and adversely affected.”

Annual report 2025A · The company itself

“We use several third-party suppliers and contract manufacturers for materials and sub-assemblies. We believe that selectively using outsourced manufacturing services allows us to focus on our core competencies in product design and development, and increases our operational flexibility.”

Annual report 2026A · The company itself

“If we were to lose any of our current supply or contract manufacturing relationships, the process of identifying and qualifying a new supplier or contract manufacturer who meets our quality and delivery requirements, and who will appropriately safeguard our intellectual property, may require a significant investment of time and resources (if an alternative supplier is available at all), adversely affecting our ability to satisfy customer purchase orders and warranty claims and delaying our ability to rapidly introduce new products to market.”

Annual report 2026A · The company itself

“Ansvarsfulla inköp Eftersom Sobi anlitar externa partners för att producera, förpacka och distribuera läkemedel sker en stor del av Sobis påverkan i värdekedjan utanför den egna verksamheten.”

Annual report 2024A · The company itself

“År 2024 besvarade 86 procent av Sobis kontraktstillverkare det obligatoriska självutvärderingsformuläret för leverantörer.”

Annual report 2024A · The company itself

“Tillverkning och montering av Ericssons kommunikationsutrustning sker både vid Bolagets egna tillverkningsanläggningar och hos tredjepartsleverantörer av elektronik. År 2024 tillverkades 78 % (86 %) av den elektroniska utrustningen som producerades av kontrakterade leverantörer för elektroniktillverkning.”

Annual report 2024A · The company itself

“Currently, we rely on suppliers such as Panasonic and Contemporary Amperex Technology Co. Limited (CATL) for these cells.”

Annual report 2025A · The company itself

“Manufacturing We outsource the manufacturing of many of our hardware products to our key contract manufacturing partners, which include Jabil and Benchmark Electronics Inc. Our contract manufacturing partners are responsible for significant material procurement, assembly, and testing.”

Annual report 2026A · The company itself

“We have experienced disruption in our supply chain and related events, and are subject to ongoing supply chain risks We are dependent upon a limited number of contract manufacturers for the manufacture, testing, and assembly of certain products and specific suppliers for a number of our critical components. These arrangements can generally be terminated with a limited notice.”

Annual report 2026A · The company itself

“Our current reliance on a limited group of contract manufacturers and suppliers involves risks, including the potential inability to obtain products or components to meet customers’ delivery requirements, reduced control over pricing and delivery schedules, and discontinuation of or increased prices for certain components.”

Annual report 2026A · The company itself

“We rely on third-party manufacturers to produce or process cell culture reagents and gene-editing components, such as Cas9 protein and guide RNA molecules, for clinical trials and commercial supply of CASGEVY, and to generate gene-edited cells to supply CASGEVY.”

Annual report 2025A · The company itself

“We also rely on third-party manufacturers to produce drug substance and finished drug product for clinical trials for povetacicept.”

Annual report 2025A · The company itself

“In connection with our API business divestiture, we entered into a manufacturing and supply agreement pursuant to which we purchase a significant amount of API from the purchaser in that transaction. Our obligations under this manufacturing and supply agreement have made us more dependent on the purchaser of our API business and the success of their business, and made us more vulnerable to API supply shortages and price volatility.”

Annual report 2025A · The company itself

“Taloudellinen katsaus Yrityksen valmistusja kokoonpanomalli on pääomakevyt. Siinä keskeistä ovat pitkäjänteiset suhteet kansainväliseen toimittajaverkostoon, joka käsittää noin 5 500 suoraa maailmanlaajuista materiaalitoimittajaa.”

Annual report 2024A · The company itself

“Toimitusketjun hallinta Toimittajat ja yhteistyökumppanit ovat tärkeä ja kiinteä osa Wärtsilän tuotteiden ja palveluiden kokonaisarvoketjua. Laajaan toimittajaverkostoon kuuluu lähes 24 000 aktiivista toimittajaa.”

Annual report 2024A · The company itself

“Toimittajat ja yhteistyökumppanit ovat tärkeä osa Wärtsilän tuotteiden ja palveluiden kokonaisarvoketjua. Toimittajaverkosto on laaja, siihen kuuluu lähes 24 000 aktiivista toimittajaa.”

Annual report 2024A · The company itself

“Risker och riskhantering, fortsättning Medel Låg Hög Område Risker Hantering Sannolikhet och effekt Leverantörskedja Risker kopplade till beroende av leverantörers åtaganden Som mindre bolag utan egen tillverkningskapacitet är Xbrane beroende av både kontraktstillverkare och kontraktslaboratorier för tillverkning och kontroll av både utvecklingsprodukter och kommersiella produkten Ximluci ® . Det finns därmed risker kopplat till att dessa leverantörer inte uppfyller sina åtaganden kring kvalitet, tidsplaner och kostnad vilket kan påverka Xbrane negativt.”

Annual report 2024A · The company itself

“We concentrate on innovative drug discovery and building robust global collaborations that enhance our manufacturing and commercialization capacity.”

Annual report 2025A · The company itself

“Upholding high standards in our supply chain We outsource selected manufacturing and clinical operations to qualified partners and maintain strict oversight to ensure consistent adherence to Good Practices (GxP). Supplier selec-tion and monitoring are governed by clear policies, proce-dures, and multiple controls, with partners chosen through a rigorous process assessing ethics, business continuity, and operational capability.”

Annual report 2025A · The company itself

“Scope 3.1 Purchased goods and services Emissions from purchased goods and services represent the largest share of Zealand Pharma’s carbon footprint and our most significant long-term decarbonization opportunity. These emissions primarily arise from outsourced research and development activities across our value chain.”

Annual report 2025A · The company itself

“We are not able to exercise direct control over the assembly or related operations of certain of our products. If these electronics manufacturers experience business difficulties or fail to meet our manufacturing needs, then we may be unable to satisfy customer demand, lose sales, and be unable to maintain customer relationships. Longer production lead times may result in shortages of certain products and inadequate inventories during periods of unanticipated higher demand.”

Annual report 2025A · The company itself

“Manufacturing and Outsourcing Final assembly of our hardware products is performed by third parties, including electronics manufacturing services companies (“EMSs”) and joint design manufacturers (“JDMs”). Our products are produced in facilities primarily located in the Asia-Pacific region (China, Malaysia, Vietnam, and Taiwan) and Mexico.”

Annual report 2025A · The company itself

“Final assembly of certain of our hardware products is performed by third party electronics manufacturers, including EMSs and JDMs. We may be dependent on such electronics manufacturers as a sole-source of supply for the manufacture of such products. A failure by such electronics manufacturers to provide manufacturing services to us as we require, or any disruption in such manufacturing services up to and including a catastrophic shut-down, may adversely affect our business results.”

Annual report 2025A · The company itself

“Manufacturing and Supply Chain Our products are manufactured at sites operated by us and sites operated by third-party contract manufacturing organizations, which we refer to as CMOs. We have a global manufacturing network of 21 sites operated by us.”

Annual report 2025A · The company itself

“We also employ a network of over 90 third-party CMOs. Many of our products involve complex manufacturing processes and are sole-sourced from certain manufacturing sites. Minor deviations in our or our suppliers' manufacturing or logistical processes, such as temperature excursions or improper package sealing, could result in delays, inventory shortages, unanticipated costs, product recalls, product liability and/or regulatory action.”

Annual report 2025A · The company itself

“Other business activities Other business activities includes our Client Supply Services contract manufacturing results, our human health business and expenses associated with our dedicated veterinary medicine research and development organization, research alliances, U.S. regulatory affairs and other operations focused on the development of our products.”

Annual report 2025A · The company itself

“Tasquinimod Laquinimod Naptumomab Produktion Active Biotech har ingen egen tillverkning varför bolaget är beroende av underleverantörer för tillverkning av läkemedelssubstanser och läkemedelsprodukter och produktion för preklinisk och klinisk utveckling.”

Annual report 2024A · The company itself

“One of Europe's leading EMS businesses. Manufacturer of electronics, mechanics, cable harnessing and mechatronics.”

Annual report 2025A · The company itself

“We also purchase electronic device components from a variety of suppliers and use several contract manufacturers to provide manufacturing services for our products. During the normal course of business, in order to manage manufacturing lead times and help ensure adequate supply, we enter into agreements with contract manufacturers and suppliers for certain electronic device components.”

Annual report 2025A · The company itself

“Our Commercial Agreements, Strategic Alliances, and Other Business Relationships Expose Us to Risks We provide physical, e-commerce, and omnichannel retail, cloud services, and other services to businesses through commercial agreements, strategic alliances, and business relationships. Under these agreements, we provide web services, technology, fulfillment, computing, digital storage, and other services, as well as enable sellers to offer products or services through our stores.”

Annual report 2025A · The company itself

“In supply chain and sourcing, Anora advanced initiatives aimed at improving efficiency and flexibility. Actions during the year included portfolio simplification, inventory reduction and value management initiatives, as well as progress in supply chain optimisation and contract manufacturing.”

Annual report 2025A · The company itself

“We use qualified vendors, including contract manufacturers, to supply parts, services and product support.”

Annual report 2025A · The company itself

“Accordingly, some key parts may be obtained from only a qualified single supplier or a limited group of qualified suppliers.”

Annual report 2025A · The company itself

“Equipment used in data centers is mostly from our Strategic and Gold partners who generally complies with EU regulations. The Supplier Code of Conduct ensures these partners are reliable, embedding responsible business conduct and adherence to environmental standards throughout the supply chain.”

Annual report 2024A · The company itself

“Skretting continues to partner as our global feed supplier, and we entered into an agreement in 2021 that aims to secure local feed supply in the future.”

Annual report 2024A · The company itself

“AutoStore will also strengthen its supply capacity through a new assembly site in APAC, by growing local supplier bases and by increasing purchasing capacity among local suppliers. Most components in the AutoStore system are sourced from multiple suppliers, while final assembly (and thus the highest value-adding activity) is done in-house.”

Annual report 2022A · The company itself

“We also have a global sourcing operation to design, develop, test and contract-manufacture our exclusive brands products.”

Annual report 2026A · The company itself

“Vi har också påbörjat utrullningen av strategiska outsourcinginitiativ för en mer konsoliderad och kostnadseffektiv tillverkning vilket innebär bättre flexibilitet inom vilka geografier vi producerar.”

Annual report 2024A · The company itself

“(F) Risker relaterade till samarbetspartner En del av BioArctics verksamhet och affärsmodell är att ingå licens- och samarbetsavtal med läkemedels- och biofarmaföretag för utveckling och försäljning av potentiella produkter. Även tillverkning och utförande av kliniska prövningar är utlagda på tredje part, kontraktstillverkare (CMO) respektive forskningsorganisationer (CRO), som en del av strategin.”

Annual report 2024A · The company itself

“Dessa intäkter är oregelbundna till sin natur. ■ INTÄKTERFRÅNANTIKROPPSTILLVERKNING ■ ■ Främst intäkter från processutveckling och tillverkning åt externa kunder. Intäkterna varierar med BioInvents behov av produktion för egna projekt.”

Annual report 2024A · The company itself

“BioInvent Manufacturing är en affärsenhet inom BioInvent International AB som erbjuder kontraktsproduktion till externa kunder.”

Annual report 2024A · The company itself

“Genom att använda ”single use”- teknologi har BioInvent Manufacturing i mer än 30 år producerat läkemedelssubstanser för kliniska prövningar i Europa, USA, Japan och Australien. möjlighet att tillverka och sälja antikroppar till externa parter. ”Som Manufacturing Scientist på BioInvent är min huvuduppgift att producera högkvalitativa monoklonala antikroppar i stora mängder för våra kliniska prövningar. Att ha egen GMP-tillverkningskapacitet är en av BioInvents främsta styrkor eftersom det gör det möjligt för oss att planera och genomföra våra studier oberoende av tredjepartsleverantörer.”

Annual report 2024A · The company itself

“Nettoomsättningen uppgick till 44,7 MSEK (71,5). Intäkter under perioden utgjordes huvudsakligen av intäkter från produktion av antikroppar för kliniska studier och intäkter från forskningstjänster.”

Annual report 2024A · The company itself

“We operate a primarily outsourced manufacturing business model that principally utilizes CMs, such as third-party wafer foundries.”

Annual report 2025A · The company itself

“The F2 ServiceBuilder is a highly efficient no-code configuration tool that enables customers and partners to configure and maintain the F2 platform according to their individual requirements. This supports process sovereignty and is a key enabler of the F2-for-partners strategy, allowing scalable growth through a partner ecosystem.”

Annual report 2025A · The company itself

“Leveraging these architectural advantages, cBrain has begun establishing a partner channel in which certified partners take responsibility for the delivery and configuration of F2 solutions. This enables cBrain to scale globally without being constrained by internal organizational capacity, while maintaining the benefits of standard software.”

Annual report 2025A · The company itself

“We rely on our outsource partners, including offshore partners, to execute and deliver on certain business processes within the organization. While we make significant effort to conduct appropriate diligence before entering into arrangements with an outsourcing partner, failure by these outsource partners to meet their contractual, regulatory, and other obligations to us, including cybersecurity protections, or our failure to adequately monitor their performance, could negatively impact our operations, expected cost savings or efficiencies, and could result in work stoppages, strikes, or performance issues with such outsource partners.”

Annual report 2025A · The company itself

“We also operate businesses which depend upon the regulatory approval of the products they manufacture for their CDMO clients.”

Annual report 2025A · The company itself

“We also purchase assemblies and turnkey solutions from contract manufacturers, based on our proprietary designs.”

Annual report 2026A · The company itself

“We also utilize contract manufacturers and strategic suppliers.”

Annual report 2026A · The company itself

“Table of Contents We have made and may continue to make investments and acquisitions to improve the speed, accuracy and efficiency of our supply chains and delivery channels. The effectiveness of these investments can be less predictable than opening new locations and might not provide the anticipated benefits or desired rates of return.”

Annual report 2025A · The company itself

“We have also entered into distribution arrangements to leverage existing distributors (including wholesalers) already engaged in the distribution of drugs, devices and/or products in the diabetes marketplace.”

Annual report 2025A · The company itself

“Manufacturing and Distribution ​ We manufacture most of our products and related equipment in Company-operated manufacturing facilities. Some products are also produced for us by third-party contract manufacturers.”

Annual report 2025A · The company itself

“EOG does not own drilling rigs or hydraulic fracturing equipment. All of EOG's drilling and completion activities are conducted on a contractual basis with independent drilling contractors and other third-party service contractors.”

Annual report 2025A · The company itself

“Episurf Medicals nuvarande produktionsstrategi innebär att kontraktstillverkare används för all produktion. Externa kontraktstillverkare ger skalbarhet och fullgod kontroll över tillverkningsprocessen samtidigt som risken för att tillväxtmöjligheterna ska begränsas av bristande produktionskapacitet minskar.”

Annual report 2024A · The company itself

“Although we enter into contracts with our design and engineering services customers, we often design and develop products for these customers prior to receiving a purchase order or other firm commitment from them. We are required to make substantial investments in the resources necessary to design and develop these products, and no revenue may be generated from these efforts if our customers do not approve the designs in a timely manner or at all.”

Annual report 2026A · The company itself

“In manufacturing, Genmab focuses on developing scalable efficient, and sustainable production processes. While we partner with contract manufacturing organizations (CMOs) for manufacturing and production, we maintain strict oversight and quality control to ensure product consistency and compliance with global standards.”

Annual report 2025A · The company itself

“In this regard, it is crucial for the CSR work that Glunz & Jensen's production strategy and value chain management is based to a large extent on an outsourcing model. Virtually all manufacturing of parts takes place with a large number of subcontractors, after which Glunz & Jensen is responsible for product assembly and distribution.”

Annual report 2025A · The company itself

“Management and the Board are fully aligned behind an ambitious agenda to accelerate growth, scale our capabilities, and realize the company’s longterm potential. Our priorities are clear: Strengthen our internal pipeline and clinical development capabilities Expand our therapeutic footprint beyond obesity Continue to deliver world-class, specialized preclinical CRO services Drive innovation across our technology platforms Establish Gubra Ventures to amplify value creation Uphold sustainability as a fundamental part of who we are To our colleagues, partners, and shareholders: thank you for your trust, collaboration, and continued belief in Gubra’s mission.”

Annual report 2025A · The company itself

“Gubra CRO — our value enabler Gubra’s CRO business is our value enabler, delivering highly specialized preclinical services to pharma and biotech customers worldwide. We help customers make fast, data-driven decisions by combining deep scientific expertise with advanced technologies.”

Annual report 2025A · The company itself

“We enable customers to make fast, data-driven decisions by combining deep scientific expertise with advanced technologies. Our capabilities span a comprehensive catalogue of translational disease models and cutting-edge platforms in areas such as metabolic, fibrotic, and CNS disorders.”

Annual report 2025A · The company itself

“Vi kombinerar tillverkningsteknologier såsom tunnplåtsmekanik, elektroniktillverkning, svetsning, kablage, skärande bearbetning och montering i fabriksparker som benämns Tillverkningskluster.”

Annual report 2024A · The company itself

“Kassaflöde från löpande verksamhet MSEK Rörelsemarginal EBITA % (Före engångsposter) 2,2 5,6 8,3 6,0 5,7 INVESTMENT CASE I början av 2024 slutförde vi förvärvet av Orbit One, en av Nordens ledande kontraktstillverkare av elektronik.”

Annual report 2024A · The company itself

“HANZAs affärsmodell är att utveckla och erbjuda tillverkningslösningar och rådgivande tjänster för att öka tillväxt och vinst för bolagets kunder. Konkret sker det dels genom att HANZA utvecklar fabriksparker och tillverkningskluster, där produkter kan tillverkas rationellt, till lägre kostnad och med en mindre miljöpåverkan, jämfört med traditionella kontraktstillverkare. Det sker även då HANZA utvecklar värdeskapande rådgivningstjänster kopplade till produkttillverkning.”

Annual report 2024A · The company itself

“Manufacturing and Materials We utilize outsourced manufacturers around the world to manufacture HP-designed products to generate cost efficiencies, reduce time to market, and maintain flexibility in our supply chain and manufacturing processes. We also manufacture finished products from components and sub-assemblies that we acquire from a wide range of vendors.”

Annual report 2025A · The company itself

“Supply chain IDEX operates with an asset light, fabless business model, leveraging external manufacturing partners to produce, assemble and test products.”

Annual report 2024A · The company itself

“IDEX Biometrics sells its products and solutions directly to manufacturers or enterprises and in some cases through distributors and resellers. Customers of IDEX Biometrics are smart card manufacturers and system integrators of the Company’s hardware and software biometric technologies.”

Annual report 2024A · The company itself

“Life Science Den 31 januari förvärvades MeHow Medical Ireland Ltd., Irland, med en årsomsättning om 160 mkr. MeHow är en utvecklingspartner och tillverkare av formsprutade komponenter för den globala medicinteknikindustrin.”

Annual report 2024A · The company itself

“As a result, to improve the financial viability of our continued development of leading-edge semiconductor process technologies and the utilization of our manufacturing assets, a few years ago we started transitioning our semiconductor manufacturing business from one that has historically been designed to serve our internal product groups into a customer-centric foundry business designed to also serve third-party external semiconductor customers. Our foundry strategy was also designed to enable us to participate in the increasing demand for U.S.-based foundry capacity and a more secure, resilient and balanced semiconductor supply chain.”

Annual report 2025A · The company itself

“In 2025, we ramped Intel 18A into high-volume production and are seeking to establish it as our first significant node for government and enterprise foundry customers. We enhanced operational processes and quality systems to meet the rigorous standards expected in the foundry industry, and continued investing in ecosystem enablement to make our manufacturing network accessible to third-party external customers, including support for industry-standard EDA tools, process design kits and a broad portfolio of foundation IP that customers can utilize as a part of their designs.”

Annual report 2025A · The company itself

“In addition to manufacturing our own products, we offer third-party foundry services to external customers and aim to establish this business as a leading external foundry.”

Annual report 2025A · The company itself

“• All volymproduktion sker med hjälp av kontraktstillverkare, vilket möjliggör både effektiv hantering av variationer i orderingången och skalbarhet. • INVISIO är skuldfritt och har en god finansiell ställning.”

Annual report 2024A · The company itself

“Uppströms Kort, medellång och lång sikt Tillverkningen av INVISIOs produkter är utlagd på kontraktstillverkare. Företaget är därigenom beroende av extern arbetskraft, såsom anställda hos samarbetspartners och underleverantörer. Produktionen av INVISIOs produkter är utlagd på ett begränsat antal kontraktstillverkare.”

Annual report 2024A · The company itself

“Det finns risk att tillverkare och leverantörer inte levererar enligt ingångna avtal och byte av leverantörer kan vara både kostsamt och tidskrävande och kvalitet, kvantitet och villkor kan avvika från ursprungliga leverantörers. IRLAB:s kvalitetsprocesser inkluderar noggrann utvärdering för att säkra kompetens samt erfarenhet innan påbörjat samarbete och därmed minska risken för problem.”

Annual report 2024A · The company itself

“IRLAB outsourcar en stor del av det praktiska genomförandet av de kliniska studierna till specialiserade samarbetspartners (Clinical Research Organizations, CRO). sop cro Källa: Infront Aktien IRLAB:s aktie av serie A är noterad på Nasdaq Stockholms huvudlista sedan den 30 september 2020, efter en flytt från Nasdaq First North Premier Growth Market där bolaget varit listat sedan 28 februari 2017.”

Annual report 2024A · The company itself

“IRL757 i klinisk Fas I - fullt finansierad till PoC I maj ingick IRLAB ett avtal med MSRD/Otuska om ett forskningssamarbete för att driva utvecklingen av IRL757, som utvecklas för behandling av apati, till klinisk Proof-of- Concept. IRLAB erhöll 3 miljoner USD i upfrontbetalning och möjlighet till ytterligare 5,5 miljoner USD i milstolpsbetalningar.”

Annual report 2024A · The company itself

“The Company derives its revenue from providing comprehensive electronics design, production and product management services.”

Annual report 2025A · The company itself

“These include automated assembly of printed circuit boards as well as higher-level system integration. We also provide various related services, ranging from development and design, through industrialization, sourcing, and logistics, to manufacturing, redesigning and upgrading products to extend their lifespan.”

Annual report 2024A · The company itself

“We also enter into co-manufacturing arrangements with third parties if we determine it is advantageous to outsource the production of any of our products.”

Annual report 2025A · The company itself

“Affärsområdena Demolition & Tools och Systems Solutions utför i huvudsak sammansättning av inköpta komponenter till färdiga slutprodukter.”

Annual report 2024A · The company itself

“Montering av produkterna sker i Sverige medan komponenttillverkningen sker hos kontraktstillverkare.”

Annual report 2024A · The company itself

“Certain of our products, devices and components are manufactured by third parties, and their failure to comply with these regulations has affected and could in the future adversely affect us, including through failure to supply product to us or delays in approvals of new products or indications.”

Annual report 2025A · The company itself

“Unimedics egen tillverkningsenhet erbjuder också kontraktstillverkning av sterila och icke-sterila flytande läkemedel till partners.”

Annual report 2024A · The company itself

“Medistim assembles and manufactures its devices and probes in Horten, Norway, except for the imaging probes which are produced by third parties.”

Annual report 2024A · The company itself

“A significant portion of Metso’s manufacturing is outsourced, emphasizing the importance of responsible procurement practices.”

Annual report 2025A · The company itself

“Midsummer utvecklar, tillverkar och säljer även utrustning för produktion av tunnfilmssolceller som nyckelfärdiga solcellsfabriker till strategiskt utvalda samarbetspartners globalt samt maskiner för forskning och utveckling till universitet och forskningsinstitut.”

Annual report 2024A · The company itself

“As part of our efforts to streamline operations and to manage capital investments, we outsource aspects of our manufacturing processes and other functions and continue to evaluate additional outsourcing. If our contract manufacturers or other outsourcers fail to perform their obligations in a timely manner or at satisfactory quality levels, our ability to bring products to market and our reputation could suffer.”

Annual report 2025A · The company itself

“Tillverkare söker pålitliga återförsäljare för att hantera lokala marknader och effektivisera sina affärsprocesser. Momentum Group erbjuder expertis och marknadskännedom som stärker värdekedjan och säkerställer att slutkundernas behov möts.”

Annual report 2024A · The company itself

“Manufacturing We utilize a fabless business model, working with third parties to manufacture, assemble and test our ICs. This fabless approach allows us to focus our engineering and design resources on our strengths and to reduce our fixed costs and capital expenditures.”

Annual report 2025A · The company itself

“Table of Contents Manufacture and Distribution AFF develops and manufactures the primary flavors for our Monster Energy® Drinks segment at its facilities in California and Athy, Ireland. In 2025, we continued to outsource the manufacturing process for the majority of our finished goods energy drink products to third-party bottlers and contract packers. In addition, we manufacture Bang Energy® drinks and certain of our other energy drink products at our manufacturing facilities in Phoenix, AZ and Norwalk, CA.”

Annual report 2025A · The company itself

“In addition to producing crop nutrients, Mosaic Fertilizantes purchases phosphate, potash and nitrogen products which are either used to produce blended crop nutrients (“Blends”) or for resale. In 2025, Mosaic Fertilizantes purchased 1.0 million tonnes of phosphate-based products, primarily MicroEssentials®, from our Phosphate segment, and 2.0 million tonnes of potash products from our Potash segment and Canpotex.”

Annual report 2025A · The company itself

“We engage with global contract manufacturers who manufacture the majority of our products across a diverse network of manufacturing locations worldwide, including facilities for our products in Mexico and Malaysia. We also manufacture, assemble, customize, stage and integrate products in the U.S.”

Annual report 2025A · The company itself

“We rely on third-parties to develop, design and/or manufacture many of our components and some of our products (including software), and to assist in performing certain IT, network connectivity, HR information systems, manufacturing, repair, distribution and engineering services. As we outsource more of such operations, we are not able to directly control these activities.”

Annual report 2025A · The company itself

“I fokus står behovet av en stark och säker försörjningskedja med de gemensamma principerna: Slutmontering nära kund. Vertikal integration och ökad insourcing.”

Annual report 2024A · The company itself

“If any of our strategic partners in alliances we currently engage with or may engage with in the future were to encounter financial 23 difficulties or change their business strategies, they may no longer be able or willing to participate in these groups or alliances, which could have a material adverse effect on our business, financial condition and results of operations.”

Annual report 2025A · The company itself

“Trends, Risks and Uncertainties Related to Our Business The manufacturing and other operations required to produce our products are highly dependent on the efficient operation of numerous processes, including processes contingent upon third-party component manufacturers and other service providers, and any disruption in these processes could have a material adverse effect on our business and results of operations.”

Annual report 2025A · The company itself

“Our business operations, productivity and customer relations could be materially adversely affected if these contractual relationships were disrupted or terminated, the cost of such services increased significantly, the quality of the services deteriorated or our forecasted needs proved to be materially incorrect.”

Annual report 2025A · The company itself

“Yhtiö on riippuvainen sopimusvalmistajistaan toimivan ja tehokkaan tuotannon järjestämisessä sekä tuotteiden kokoamisessa.”

Annual report 2025A · The company itself

“We outsource most of our manufacturing, assembly, delivery and technology of, and certain component designs for, our hardware products to a variety of companies, many of which are located outside the U.S. From time to time, these partners experience production problems or delays or cannot meet our demand for products on a timely or cost-effective basis, including as a result of changes to trade laws or regulations, tariffs, sanctions and export or import controls.”

Annual report 2026A · The company itself

“Costs associated with our hardware business include the cost of hardware products, which consists of expenses for materials and labor used to produce these products by our internal manufacturing operations or by third-party manufacturers; the cost of materials used to repair customer products with eligible support contracts; the cost of labor and infrastructure to provide support services; and sales and marketing expenses, which are largely personnel-related and include variable compensation earned by our sales force for the sales of our hardware offerings.”

Annual report 2026A · The company itself

“Høydepunkter i 2024 Den organiske omsetningsveksten var på 8,7 %, drevet av volumvekst i det norske markedet og kontraktsproduksjon.”

Annual report 2024A · The company itself

“Growth driven by higher manufacturing of third-party products under manufacturing and supply agreements, higher manufacturing-related services and higher active pharmaceutical ingredient sales.”

Annual report 2025A · The company itself

“Additionally, we purchase electronic devices, which are made by various electronic manufacturing services providers ("EMS"). The components used in the assembly of these devices can be made by the EMS or purchased from other suppliers. These components include mechanical parts, electrical and electromechanical components, batteries, semiconductors, and packaging materials.”

Annual report 2025A · The company itself

“We increasingly rely on third-parties and their subcontractors/suppliers, sometimes concentrated in a specific geographic area, for product distribution and to manufacture some of our products and product parts (particularly, electronic devices and accessories), as well as to provide services, including to support our finance, commercialization and information technology processes. While many of these arrangements improve efficiency and decrease our operating costs, they also diminish our direct control.”

Annual report 2025A · The company itself

“As a business with outsourced manufacturing and logistics, Photocure relies on suppliers, individuals or organizations who provide goods and services to the company. Photocure is thereby directly and indirectly exposed to risks and opportunities in its business relations and supply chain.”

Annual report 2024A · The company itself

“Polaris Trykk trykker papiravisene til nesten samtlige av konsernets mediehus i Norge. Utover konsernets egne aviser, har trykkeriene en betydelig portefølje av oppdrag for eksterne kunder.”

Annual report 2024A · The company itself

“Under 2023 tecknade vi ett strategiskt viktigt avtal med Bosch om kontraktstillverkning av bränslecellsstacken S3 åt PowerCell.”

Annual report 2024A · The company itself

“Funktioner som inte hör till kärnverksamheten, så som produktion, lager, logistik, redovisning, IT-tjänster samt reparationer, outsourcas.”

Annual report 2024A · The company itself

“Under alla faser i utvecklingen kan Bolaget, baserat på sin granskning av tillgängliga kliniska data, uppskattade kostnader för fortsatt utveckling, marknadsöverväganden eller andra faktorer, komma att lägga Produktionsrisker Produktion av ASTar instrumentet sker hos en internationell kontraktstillverkare med dotterbolag i Sverige men med global produktionskapacitet. Denna globala kontraktstillverkare har möjlighet att flytta produktion till andra regioner om detta skulle vara önskvärt. Förbrukningsartiklar produceras främst i egen regi i hyrda produktionslokaler i Uppsala medan vissa delmoment av produktionen sker hos kontraktstillverkare i Sverige och Tyskland.”

Annual report 2024A · The company itself

“Det finns också risk för bristande eller uteblivna leveranser från nuvarande eller framtida leverantörer för tillverkning av instrument samt för att en eller flera av Bolagets nuvarande eller framtida leverantörer väljer att avbryta sitt samarbete med Bolaget (t.ex. om en leverantör blir uppköpt av en konkurrent till ned utvecklingen av sina planerade produkter. Om någon av Bolaget), eller att priset för deras varor och tjänster väsentligt förändras. Bolaget har för närvarande inte säkerställt att det finns alternativa leverantörer (s.k. second source) för Bolagets samtliga komponenter och produkter, vilket innebär att det kan bli mycket kännbart om leveranser brister eller uteblir, eller om överenskomna priser väsentligen förändras.”

Annual report 2024A · The company itself

“If we are unable to arrange for sufficient production capacity among our suppliers or contract manufacturers, or if our suppliers or contract manufacturers encounter production, quality, financial or other difficulties (including due to labor or geopolitical disturbances or natural disasters), we may be unable to meet our customers’ demands.”

Annual report 2025A · The company itself

“We also currently rely entirely on other parties (such as contract manufacturers) and our collaborators for filling and finishing services, and expect to increase our reliance on other parties and/or our collaborators for bulk product manufacturing in the future.”

Annual report 2025A · The company itself

“Scanfil sources most of the purchased goods and services in the form of materials and components that are used in the manufacturing of customer-designed products and sub-assemblies. These include system integration, printed circuit board assembly (PCBA), and box builds. The company’s production is based on customer specifications, but customers also request Scanfil to align with their set sustainability goals, particularly regarding transparency in lifecycle emissions and carbon reduction targets.”

Annual report 2025A · The company itself

“Risker relaterade till samarbeten med leverantörer och tillverkare SynAct är beroende av samarbeten med leverantörer och tillverkare och har bland annat ingått avtal med leverantörer som tillhandahåller tjänster och produkter för läkemedelsproduktion samt genomförande av bolagets planerade kliniska studier. Bolaget är därutöver, och kommer sannolikt även fortsättningsvis vara, beroende av samarbeten med olika leverantörer och kontraktstillverkare för tillverkning och förvaring av GMP-material (Eng. Good Manufacturing Practice) och de substanser som krävs för genomförande av SynActs prekliniska och kliniska studier.”

Annual report 2024A · The company itself

“We rely on third-party software developers for the development of some of our titles. Quality third-party developers are continually in high demand, and those who have developed titles for us in the past may not be available to develop software for us in the future. Due to the limited availability of third-party software developers and the limited control that we exercise over them, these developers may not be able to complete titles for us on a timely basis or within acceptable quality standards, if at all.”

Annual report 2026A · The company itself

“We may rely on third-party suppliers for the components used in our products, and we may rely on third-party manufacturers to manufacture certain of our assemblies and finished products. Our results of operations, financial position, and cash flows could be adversely affected if such third parties lack sufficient quality control or if there are significant changes in their financial or business condition.”

Annual report unknown yearA · The company itself

“Yksikkö kehittää, suunnittelee ja valmistaa itse suuren osan tuotteistaan. Sen tuotekehitysyksiköt toimivat Suomessa ja Belgiassa. Tuotanto tapahtuu omassa tehtaassa Suomessa ja kumppaneiden tehtaissa Aasiassa ja Meksikossa.”

Annual report 2025A · The company itself

“We subcontract a portion of our wafer fabrication and assembly and testing of our products, and we depend on third parties (including contractors and other service providers) to support key portions of our operations (including manufacturing operations and advanced logic manufacturing process technology development) and to construct our facilities. We do not have long-term contracts with all of these suppliers, and the number of alternate suppliers is limited.”

Annual report 2025A · The company itself

“In 2025, we sourced the majority of our wafer fabrication, as well as assembly and test, internally. To supplement our internal manufacturing capacity, we selectively use the capacity of outside suppliers, commonly known as foundries and subcontractors.”

Annual report 2025A · The company itself

“Some of our OEM customers have adopted a subcontractor model that requires us to contract directly with companies, such as ODMs, that provide manufacturing and fulfillment services to our OEM customers. Because these subcontractors are generally not as well capitalized as our direct OEM customers, this subcontractor model exposes us to increased credit risks.”

Annual report 2026A · The company itself

“The Company also relies on third-party subcontractors to assemble and test a portion of its products. The Company does not have long-term contracts with some of these subcontractors and cannot directly control product delivery schedules or manufacturing processes.”

Annual report 2026A · The company itself